mild cognitive impairment
Cytox Gets CE Mark for Alzheimer's Disease Genetic Risk Test
The polygenic risk test analyzes an individual's genes for more than 100,000 SNPs associated with the risk of developing Alzheimer's disease.
DiamiR Wins $3.9M in NIH Funding for Neurological Disease Diagnostic Development
The two grants awarded will support DiamiR's development of microRNA diagnostics for mild cognitive impairment, Alzheimer's disease, and Rett syndrome.
Alzheimer's Disease Neuroimaging Initiative Enters Third Phase
The initiative was launched to conduct a large-scale study of cognitive impairment and Alzheimer's disease to advance the discovery of biomarkers of the conditions.
Affymetrix, Cytox Partner on Alzheimer's Disease Risk Dx
The partners will collaborate on the development of a custom SNP panel to predict an individual's Alzheimer's disease or MCI risk.
Estonian Population Profiling Reveals Recurrent, Rare CNVs Linked to Intellectual Ability
More than 10 percent of individuals in an unselected population carried recurrent syndrome-associated CNVs or rare autosomal CNVs with potential ties to cognitive ability.